Announcement

Collapse
No announcement yet.

Diagnosis (Berl) . Clinical assessment of the Roche SARS-CoV-2 rapid antigen test

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Diagnosis (Berl) . Clinical assessment of the Roche SARS-CoV-2 rapid antigen test


    Diagnosis (Berl)


    . 2021 Jan 18;dx-2020-0154.
    doi: 10.1515/dx-2020-0154. Online ahead of print.
    Clinical assessment of the Roche SARS-CoV-2 rapid antigen test


    Gian Luca Salvagno 1 2 , Gianluca Gianfilippi 3 , Damiano Bragantini 4 , Brandon M Henry 5 , Giuseppe Lippi 2



    Affiliations

    Abstract

    Objectives: Novel point-of-care antigen assays present a promising opportunity for rapid screening of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The purpose of this study was the clinical assessment of the new Roche SARS-CoV-2 Rapid Antigen Test.
    Methods: The clinical performance of Roche SARS-CoV-2 Rapid Antigen Test was evaluated vs. a reverse transcription polymerase chain reaction (RT-PCR) laboratory-based assay (Seegene AllplexTM2019-nCoV) in nasopharyngeal swabs collected from a series of consecutive patients referred for SARS-CoV-2 diagnostics to the Pederzoli Hospital (Peschiera del Garda, Verona, Italy) over a 2-week period.
    Results: The final study population consisted of 321 consecutive patients (mean age, 46 years and IQR, 32-56 years; 181 women, 56.4%), with 149/321 (46.4%) positive for SARS-CoV-2 RNA via the Seegene AllplexTM2019-nCoV Assay, and 109/321 (34.0%) positive with Roche SARS-CoV-2 Rapid Antigen Test, respectively. The overall accuracy of Roche SARS-CoV-2 Rapid Antigen Test compared to molecular testing was 86.9%, with 72.5% sensitivity and 99.4% specificity. Progressive decline in performance was observed as cycle threshold (Ct) values of different SARS-CoV-2 gene targets increased. The sensitivity was found to range between 97-100% in clinical samples with Ct values <25, between 50-81% in those with Ct values between 25 and <30, but low as 12-18% in samples with Ct values between 30 and <37.
    Conclusions: The clinical performance of Roche SARS-CoV-2 Rapid Antigen Test is excellent in nasopharyngeal swabs with Ct values <25, which makes it a reliable screening test in patients with high viral load. However, mass community screening would require the use of more sensitive techniques.

    Keywords: COVID-19; SARS-CoV-2; antigen; diagnosis; immunoassay.

Working...
X